Shares of United Therapeutics Co. (NASDAQ:UTHR) have been given a consensus recommendation of “Buy” by the eleven brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $156.57.
A number of brokerages have recently issued reports on UTHR. Wedbush boosted their target price on shares of United Therapeutics from $247.00 to $255.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. JPMorgan Chase & Co. began coverage on shares of United Therapeutics in a research report on Monday, September 14th. They issued an “overweight” rating for the company. Oppenheimer raised their target price on shares of United Therapeutics from $165.00 to $175.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. TheStreet upgraded United Therapeutics from a “c” rating to a “b-” rating in a report on Wednesday, October 28th. Finally, BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 11th.
Shares of NASDAQ UTHR opened at $151.79 on Wednesday. United Therapeutics has a 1 year low of $75.58 and a 1 year high of $152.82. The firm has a 50-day simple moving average of $140.56 and a two-hundred day simple moving average of $120.50. The company has a market cap of $6.75 billion, a P/E ratio of 15.58 and a beta of 0.71. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.43 and a quick ratio of 7.08.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $3.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.41 by $1.43. The firm had revenue of $380.10 million during the quarter, compared to analyst estimates of $357.95 million. United Therapeutics had a return on equity of 14.90% and a net margin of 30.04%. United Therapeutics’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same period last year, the company earned $3.83 EPS. As a group, equities research analysts expect that United Therapeutics will post 10.45 EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. NEXT Financial Group Inc purchased a new position in shares of United Therapeutics in the 3rd quarter valued at $26,000. FinTrust Capital Advisors LLC bought a new stake in United Therapeutics during the second quarter valued at about $51,000. Advisors Asset Management Inc. raised its holdings in United Therapeutics by 14,333.3% in the second quarter. Advisors Asset Management Inc. now owns 866 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 860 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of United Therapeutics by 36.4% during the second quarter. Rockefeller Capital Management L.P. now owns 1,125 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 300 shares during the last quarter. Finally, NuWave Investment Management LLC boosted its holdings in shares of United Therapeutics by 1,017.8% in the 3rd quarter. NuWave Investment Management LLC now owns 1,755 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 1,598 shares in the last quarter. 94.37% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
See Also: No Load Funds
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.